Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy

Zhou, Songlei; Huang, Yukun; Chen, Yu; Liu, Shanshan; Xu, Min-Jun; Jiang, Tianze; Song, Qing; Jiang, Gan; Gu, Xiao; Gao, Xiaoling; Chen, Jun

doi:10.1016/j.biomaterials.2020.119795

Cited by 74 publications

(43 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Montanide is therefore mixed with the peptides prior to vaccination to generate a water-in-oil emulsion. For efficient uptake, the peptides can be also encapsulated in structures such as liposomes 98 and nanoparticles 99 or can be covalently conjugated to adjuvants 90,92 . In multi-peptide vaccination approaches and especially in patient-individualized approaches the covalent linkage of adjuvants to each individual and single peptide is cumbersome for clinical translation.…”

Section: Adjuvants and Delivery Mode -It´s All About Activationmentioning

confidence: 99%

The Peptide Vaccine of the Future

Nelde

Rammensee

Walz

2021

Molecular & Cellular Proteomics

131

View full text Add to dashboard Cite

The approach of peptide-based anti-cancer vaccination has proven the ability to induce cancer-specific immune responses in multiple studies for various cancer entities. However, clinical responses remain so far limited to single patients and broad clinical applicability was not achieved. Therefore, further efforts are required to improve peptide vaccination in order to integrate this low side effect therapy into the clinical routine of cancer therapy. To design clinically effective peptide vaccines in the future, different issues have to be addressed and optimized comprising antigen target selection as well as choice of optimal adjuvants and vaccination schedules. Furthermore, the combination of peptide-based vaccines with other immuno- and molecular targeted therapies as well as the development of predictive biomarkers could further improve efficacy. In this review, current approaches in the development of peptide-based vaccines and critical implications for optimal vaccine design are discussed.

show abstract

Section: Adjuvants and Delivery Mode -It´s All About Activationmentioning

confidence: 99%

The Peptide Vaccine of the Future

Nelde

Rammensee

Walz

2021

Molecular & Cellular Proteomics

131

View full text Add to dashboard Cite

show abstract

“…Besides receptor-mediated endocytosis, macropinocytosis is another way to take up exogenous antigens. For example, the biomimetic nanovaccine (R837- α OVA-ApoE3-HNP) can be taken into DCs through the macropinocytosis pathway and significantly promote DC maturation, antigen presentation, and strong T cell immune responses (including the generation of antigen-specific CD8+ T cells, expansion of IFN- γ + CD8+ T cells, and the secretion of IFN- γ +) [ 46 ]. In addition, the nanoparticle can also be used as an adjuvant or immune enhancer and has the ability to activate cellular, humoral immunity and promote antigen presentation.…”

Section: Targeted Therapy Of Cells In the Tumor Immune Microenviromentioning

confidence: 99%

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy

Wang

Bao

Yao

2021

Journal of Immunology Research

View full text Add to dashboard Cite

Targeted therapy for the cancer immune system has become a clinical reality with remarkable success. Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. However, the clinical utility of immunotherapy in cancer is limited by severe off-target toxicity, long processing time, limited efficacy, and extremely high cost. Bionanomaterials combined with these therapies address these issues by enhancing immune regulation, integrating the synergistic effects of different molecules, and, most importantly, targeting and manipulating immune cells within the tumor. In this review, we will summarize the most current researches on bionanomaterials for targeted regulation of tumor-associated macrophages, myeloid-derived suppressor cells, dendritic cells, T lymphocyte cells, and cancer-associated fibroblasts and summarize the prospects and challenges of cell-targeted therapy and clinical translational potential in a tumor immune microenvironment in cancer treatment.

show abstract

“…While most studies have focused on designing nanoparticles to target DCs based on receptor-mediated endocytosis [50][51][52][53][54], macropinocytosis also showed favorable results for nanoparticle internalization. Zhuo et al [55] reported that surface modification with apolipoprotein E3 significantly enhances the uptake of nanoparticles into DCs mainly via the macropinocytotic pathway and in vivo administration of these modified nanoparticles loaded with imiquimod (an agonist against TLR7) and ovalbumin prevents lung tumor metastasis and has a significant treatment benefit when combined with an anti-PD-1 antibody in B16 melanoma-bearing mice. Efforts have also been made to generate nanoparticles that are able to carry multiple immunostimulatory agents.…”

Section: Emerging Nanoparticle-based Systems For Cancer Immunotherapymentioning

confidence: 99%

Emerging nanomedicines for effective breast cancer immunotherapy

2020

View full text Add to dashboard Cite

Breast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immunotherapy can not only eliminate the primary tumors, but also be proven to be effective in impeding metastasis and recurrence. However, the clinical application of cancer immunotherapy has faced some limitations including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells as well as uncontrolled modulation of immune system, which can give rise to autoimmunity and nonspecific inflammation. Growing evidence has suggested that nanotechnology may meet the needs of current cancer immunotherapy. Advanced biomaterials such as nanoparticles afford a unique opportunity to maximize the efficiency of immunotherapy and significantly diminish their toxic side-effects. Here we discuss recent advancements that have been made in nanoparticle-involving breast cancer immunotherapy, varying from direct activation of immune systems through the delivery of tumor antigens and adjuvants to immune cells to altering immunosuppression of tumor environment and combination with other conventional therapies.

show abstract

Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy

Cited by 74 publications

References 68 publications

The Peptide Vaccine of the Future

The Peptide Vaccine of the Future

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy

Emerging nanomedicines for effective breast cancer immunotherapy

Contact Info

Product

Resources

About